DeepHealth /
iCAD
DeepHealth agrees to acquire iCAD in $103m deal
What happened
DeepHealth agreed to buy iCAD, an AI-powered breast cancer screening company based in New Hampshire, US. The all-stock transaction values iCAD at approximately $3.61 per share on a fully diluted basis.
The transaction is expected to complete by Q3 2025, subject to customary closing conditions.
The source
Everything on this page comes from the source below.
DeepHealth agrees to acquire iCAD in $103m deal
This document is the source for the companies, stage, figure and people on this page.
Source-verifiedTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Published by the source
The source this page is built from.
Source-verifiedExpected close
The source this page is built from.
Source-verified
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request an inviteAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly